One receptor, two, or three. Semaglutide, tirzepatide and retatrutide form a deliberate ladder, and the whole reason laboratories run them side by side is to isolate what each additional receptor arm contributes.
Everything below describes what these compounds do in published in vitro and animal-model research. All three are supplied strictly as analytical reference materials for laboratory research — not as medicines, and not for human or animal use. We do not provide dosing or clinical guidance for any of them.
View Compliance PolicyThe benchmark. Long-acting single-receptor GLP-1 agonist that dual and triple compounds are measured against.
Adds GIP engagement to the GLP-1 backbone, with a deliberately balanced potency profile across both receptors.
Adds a glucagon-receptor arm on top of the dual profile, recruiting hepatic lipid mobilisation and energy expenditure.
For the specific pairings, in more depth.
They form a ladder of receptor coverage. Semaglutide engages one incretin receptor, GLP-1. Tirzepatide engages two, adding GIP. Retatrutide engages three, adding the glucagon receptor on top of both. Each step is a deliberate design choice, and the reason the three are studied together is that running them in parallel isolates what each additional receptor arm contributes — something no single compound can show on its own.
Because the comparison is the experiment. Holding the assay system constant and varying only the receptor coverage is how published work separates GLP-1 signalling from the GIP contribution, and both from the glucagon arm. Semaglutide functions as the single-receptor baseline in that design, which is why it appears in comparative work far more often than its own novelty would suggest.
In published pre-clinical and cell-culture research, retatrutide reports the largest effects on body weight and hepatic fat of the three, with tirzepatide generally exceeding single-receptor GLP-1 references. Those are research-model readouts rather than clinical claims, and potency in an assay system is not the only thing that determines which compound suits a given experiment — receptor selectivity, exposure window and assay compatibility all matter.
Roughly in the order you would expect: semaglutide is the most established and generally the least expensive per vial, retatrutide the newest and most expensive, tirzepatide between them. Compare cost per milligram at the vial size you actually need rather than headline price, since the three are supplied at different sizes and reconstitute to different working concentrations. All three are held in Metro Manila, so no customs or import charges are added after checkout.
Yes, all three are stocked in Noxa Labs Metro Manila cold storage and ship nationwide — 2–3 business days within Metro Manila, 3–5 to Greater Luzon and 5–7 to Visayas and Mindanao. Each ships with a batch COA you can verify by the code on the vial, and all three are supplied strictly as analytical reference materials for in vitro research.
Before you order. Every batch of all three is independently HPLC-tested — you can verify any batch by the code on its vial, and this guide explains how to read the report.
Browse our full catalog of third-party verified research-grade compounds.
Browse Research CatalogBehind every vial is a third-party COA, cold-storage handling, and the standards your own team would set. If you're scaling a lab, supplying a clinic, or building a research practice in the Philippines — we'd love to grow alongside you.
By purchasing from Noxa Labs, you acknowledge that you are a qualified researcher. Not for human or animal consumption.
Learn MoreTEXT our dedicated support team now and get an answer in 5-10 minutes
